Intravenous iron: out of sight, out of mind

The Lancet Haematology

Volumn 5, Issue 1, 2018, Pages e10-e12

  Auerbach, Michael ^a   Muñoz, Manuel ^b   Macdougall, Iain C ^c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ARTHRALGIA; BACKACHE; BODY WEIGHT LOSS; BRONCHOSPASM; COGNITION; COUGHING; DIARRHEA; DYSPNEA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEVER; HEADACHE; HUMAN; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; MINERAL SUPPLEMENTATION; MORBIDITY; MORTALITY RATE; MYALGIA; NAUSEA; NOTE; PREGNANCY; PRIORITY JOURNAL; PUBLIC HEALTH; STRIDOR; TACHYPNEA; URTICARIA; DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION;

HUMANS; INJECTIONS, INTRAVENOUS; IRON;

EID: 85040621203     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(17)30230-2     Document Type: Note

References (14)

1. Leahy, M, Hofmann, A, Towler, S, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. Transfusion 57 (2017), 1347–1358.
2. Lee, T, Clavel, T, Smirnov, K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metaboloma in patients with IBD. Gut 66 (2016), 863–871.
3. Anker, S, Colet, J, Filippatos, E, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 1–13.
4. Tolkien, Z, Stecher, L, Mander, A, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One, 10, 2015, e0117383.
5. Moretti, D, Goede, J, Zeder, C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice daily doses in iron-depleted young women. Blood 126 (2015), 1981–1989.
6. Stoffel, NU, Cercamondi, CI, Brittenham, G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 4 (2017), e524–e533.
7. Rampton, D, Folkersen, J, Fishbane, S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99 (2014), 1671–1676.
8. Macdougall, I, Bircher, A, Eckardt, K, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 89 (2016), 28–39.
9. Barton, J, Barton, E, Bertoli, L, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 109 (2000), 27–32.
10. Farnam, K, Chang, C, Teuber, S, et al. Non-allergic drug hypersensitivity reactions. Int Arch Allergy Immunol 159 (2012), 327–345.
11. Hoigné R, Breymann, C, Künzi, UP, Brunner, F, Parenteral iron therapy: problems and possible solutions. Schweiz Med Wochenschr 128 (1998), 528–535.
12. Macdougall, I, Vernon, K, Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol 45 (2017), 60–62.
13. Avni, T, Bieber, A, Grossman, A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 90 (2015), 12–23.
14. Chandler, G, Harchowal, J, Macdougall, I, Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 38 (2001), 988–991.